Synthesis of KIF18A inhibitor

Through improved synthesis methods and key intermediate compounds, the hygroscopicity and impurity control problems of KIF18A inhibitors are solved, and a more stable and scalable preparation process is achieved, which is suitable for drug production.

CN118922406APending Publication Date: 2024-11-08AMGEN INC
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380018655.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-26
Filing Date
2023-01-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing preparation methods for KIF18A inhibitor compounds have hygroscopic problems and unpredictable impurity control, which affects their commercial application.

Method used

Using new key intermediate compounds, such as compound 2a, compound 3a, compound 5 or compound 6a and its salts, the improved synthesis method, including amide coupling strategies and metal catalysis, is prepared with improved stability and scalability. KIF18A inhibitor.

Benefits of technology

It improves the stability and impurity control ability of the compound, reduces hygroscopicity, is suitable for commercial drug production, and provides a more reliable preparation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922406A_ABST
    Figure CN118922406A_ABST
Patent Text Reader

Abstract

The present invention relates to an improved preparation of a KIF18A inhibitor having the following chemical structure: Compound (1) # imgabs0 # or a salt thereof: Compound 1a # imgabs1 # wherein HA is as defined herein; and a key intermediate thereof having the following formula: Compound (2a), Compound (3a), Compound (5) or a salt thereof, and Compound (6a) or a hydrate thereof: Compound (2a) # imgabs2 compound (3a) # imgabs3 compound (5) # imgabs4 compound or a salt thereof; and Compound (6a) # imgabs5 # or a hydrate thereof, preferably Compound (6a-1) # imgabs6 #. The invention further relates to a solid form of Compound (6a), preferably a crystalline hydrate form of Compound (6a-1).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an improved, efficient and scalable process for preparing a KIF18A inhibitor compound, namely N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonylamino)-2-(6-azaspiro[2.5]octan-6-yl)benzamide (Compound 1) or a pharmaceutically acceptable salt thereof, which is carried out in a batch process, a continuous process or a hybrid thereof. The present invention also relates to the preparation of key intermediate compounds that can be used to prepare Compound 1 or a pharmaceutically acceptable salt thereof. The present invention further relates to a solid form of Compound 6a, preferably a crystalline hydrate form of Compound 6a (Compound 6a-I). Background Art

[0002] The free base compound 2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-[(2-hydroxyethanesulfonyl)amino]benzamide (Compound 1) or a pharmaceutically acceptable salt thereof can be used as an inhibitor of the motor protein kinesin family member 18A (KIF18A):

[0003]

[0004] Kinesins are molecular motors that play an important role in cell division and intracellular vesicle and organelle transport. Mitotic kinesins play a role in several aspects of spindle assembly, chromosome separation, centrosome separation and dynamics. Based on sequence homology within the so-called "motor domain", human kinesins are classified into 14 subfamilies; the ATPase activity of this domain drives unidirectional movement along microtubules (MTs). The non-motor domains of these proteins are responsible for cargo attachment; "cargo" can include any of a variety of different membrane organelles, information conduction scaffolding systems, and chromosomes. Kinesins use ATP hydrolysis energy to move cargo along polarized microtubules. Therefore, kinesins are often referred to as "plus end" or "minus end" directional motors.

[0005] KIF18A gene belongs to the kinesin-8 subfamily and is a plus-end directed motor. KIF18A is considered to affect the dynamics of the plus end of the centromere microtubule to control correct chromosome positioning and spindle tension. The depletion of human KIF18A leads to longer spindles in HeLa cervical cancer cells, increased chromosome oscillation (chromosomeoscillation) in metaphase and activation of mitotic spindle assembly checkpoints. KIF18A appears to be a feasible target for cancer therapy. KIF18A is overexpressed in various types of cancer, including but not limited to colon cancer, breast cancer, lung cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer and ovarian cancer. In addition, in cancer cell lines, the gene deletion or knockout of KIF18A or inhibition affects the mitotic spindle apparatus. In particular, inhibition of KIF18A has been found to induce mitotic cell arrest, a known weakness that can promote cell death in mitosis via apoptosis, mitotic catastrophe, or multipolar-driven lethality or death following mitotic slippage in interphase.

[0006] Compound 1 and exemplary methods of making it are described in U.S. Patent No. 11 / 236,069, issued on February 1, 2022, which is incorporated herein by reference in its entirety. Stable salts, hydrates, solvates or cocrystals of Compound 1, and solid forms of Compound 1 (including crystalline anhydrous Compound 1 or amorphous Compound 1), stable salts, hydrates, solvates or cocrystals of Compound 1, particularly for commercial pharmaceutical production of Compound 1, are described in U.S. Provisional Patent Application No. US 63 / 224,208, filed on July 21, 2021, which is incorporated herein by reference in its entirety.

[0007] U.S. Patent No. 11 / 236,069 discloses a method for preparing Compound 1, which relies on the introduction of a key intermediate compound in the penultimate step. It was found that the disclosed method involves a key intermediate compound with undesirable physical properties (hygroscopicity) and has an unpredictable impurity control strategy that requires multiple recrystallizations of the key intermediate compound. In order to overcome the commercial risks identified with the disclosed method, the inventors have developed a new and improved method of the present invention for preparing Compound 1 or a pharmaceutically acceptable salt thereof (preferably its HCl salt), which will improve the impurity control strategy, improve convergence, scalability, and utilize a key intermediate compound with improved stability. The key intermediate compounds of the present invention that can be used to synthesize Compound 1 or a pharmaceutically acceptable salt thereof are Compound 2a, Compound 3a, Compound 5 or its salt, and Compound 6a having the following formula:

[0008]

[0009] or its salts; Preferably, the hydrate of compound 6a is:

[0010] The new key intermediate compound is named:

[0011] (1) 4-((2-(Benzyloxy)ethyl)sulfonylamino)-N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide (Compound 2a);

[0012] (2) 4-((2-(Benzyloxy)ethyl)sulfonylamino)-2-(6-azaspiro[2.5]oct-6-yl)benzoic acid (Compound 3a);

[0013] (3) 4-nitro-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid (Compound 5);

[0014] (4) calcium 2-(benzyloxy)ethane-1-sulfinate (Compound 6a); and

[0015] (5) Calcium 2-(benzyloxy)ethane-1-sulfinate 4 / 3 hydrate (Compound 6a-I).

[0016] The present invention further relates to a solid form of compound 6a, preferably a crystalline hydrate form of compound 6a (compound 6a-I). Summary of the invention

[0017] In aspect 1 of the present invention, the present invention provides a novel method for preparing a KIF18A inhibitor having the following chemical structure:

[0018] The method comprises making a compound 2 having the following structure:

[0019] wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 Alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; react with a suitable deprotecting agent in a suitable solvent to form the compound 1.

[0020] In aspect 2 of the present invention, the present invention provides the method as described in aspect 1, wherein the method further comprises preparing the compound 2, comprising: making a compound 3 having the following formula: or its salt; wherein PG is a hydroxyl protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; and a compound 4 having the formula: or a salt thereof; reacting in an organic solvent in the presence of an amide coupling agent and a base to form the compound 2.

[0021] In aspect 3 of the present invention, the present invention provides the method as described in aspect 2, wherein the method further comprises preparing the compound 3 or a salt thereof, comprising: making a compound 5 having the following formula: or its salt; and compound 6 having the following formula: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; M is a metal, including an alkali metal, an alkaline earth metal or a transition metal, preferably sodium, calcium or zinc metal, more preferably calcium; and n is an integer selected from 1 or 2, preferably 2; or a hydrate thereof; and a base, optionally in the presence of a catalyst, in an organic solvent at an elevated temperature to form the compound 3 or a salt thereof.

[0022] In aspect 4 of the present invention, the present invention provides the method as described in aspect 3, wherein the method further comprises preparing the compound 5 or a salt thereof, comprising: making a compound 7 having the following formula: wherein X1 is a halide, preferably a chloride or a bromide, more preferably a chloride; and a compound 8 having the following formula: wherein LG1 is a leaving group, preferably halogen, more preferably chlorine or fluorine, most preferably fluorine; reacting in the presence of a base in an organic solvent at an elevated temperature to form the compound 5 or a salt thereof.

[0023] In aspect 5 of the present invention, the present invention provides the method as described in aspect 2, wherein the method further comprises preparing the compound 4, comprising: making a compound 9 having the following formula: wherein LG2 is a leaving group, preferably halogen, more preferably chlorine or fluorine, most preferably chlorine; and a compound 10 having the following formula: wherein X2 is a halide, preferably a chloride or a bromide, more preferably a chloride; reacting in the presence of a base at an elevated temperature in an organic solvent to form the compound 4.

[0024] In aspect 6 of the present invention, the present invention provides a compound, which is compound 2; wherein PG is benzyl, having the structure

[0025] In aspect 7 of the present invention, the present invention provides a compound, which is compound 3; wherein

[0026] PG is a benzyl group with the following structure:

[0027] In aspect 8 of the present invention, the present invention provides a compound, which is or a salt thereof.

[0028] In aspect 9 of the present invention, the present invention provides the method according to aspect 3, wherein the method further comprises preparing the compound 6 having the following chemical structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; M is a metal, including an alkali metal, an alkaline earth metal or a transition metal, preferably sodium, calcium or zinc metal, more preferably calcium; and n is an integer selected from 1 or 2, preferably 2; or a hydrate thereof; the method comprises making a compound 11 having the following structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; react with a base in a polar solvent at a moderately elevated temperature to form the compound 6; or preferably a hydrate thereof, most preferably

[0029] In aspect 10 of the present invention, the present invention provides the method according to aspect 9, wherein the method further comprises preparing the compound 11 by: making a compound 12 having the following chemical structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 Alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; with an oxidizing agent; in the presence of a catalyst in a solvent and at a slightly elevated temperature to form the compound 11.

[0030] In aspect 11 of the present invention, the present invention provides the method according to aspect 10, wherein the method further comprises preparing the compound 12 by: making a compound 13 having the following chemical structure: With compound 14 having the following chemical structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; and LG3 is a leaving group; preferably LG3 is halogen, more preferably fluorine, chlorine or bromine, more preferably bromine; react in the presence of a base in a solvent and at a moderately elevated temperature to form the compound 12.

[0031] In aspect 12 of the present invention, the present invention provides a method as described in aspect 1, wherein PG is benzyl and the suitable deprotecting agent is a palladium carbon catalyst.

[0032] In aspect 13 of the present invention, the present invention provides a method as described in aspect 1, wherein the solvent is a polar solvent.

[0033] In aspect 14 of the present invention, the present invention provides the method as described in aspect 13, wherein the solvent is a mixture of acetone and water.

[0034] In aspect 15 of the present invention, the present invention provides a method as described in aspect 2, wherein the amide coupling agent is selected from chloroformamidinium salt, 2-chloro-1,3-dimethylimidazolinium chloride (DMC), 1-(chloro-1-pyrrolidinylmethylene)pyrrolidinium hexafluorophosphate (PyCIU), 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) or N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).

[0035] In aspect 16 of the present invention, the present invention provides a method as described in aspect 2, wherein the base is selected from N-methylmorpholine (NMM), N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), 2,4,6-trimethylpyridine (collidine) or 2,6-lutidine.

[0036] In aspect 17 of the present invention, the present invention provides a method as described in aspect 2, wherein the chloroformamidinium salt is chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH), and the base is 2,4,6-trimethylpyridine (collidine).

[0037] In aspect 18 of the present invention, the present invention provides a method as described in aspect 2, wherein the method is carried out at a temperature of 25°C to 50°C, preferably 40°C to 50°C, more preferably 50°C.

[0038] In aspect 19 of the present invention, the present invention provides a method as described in aspect 2, wherein the solvent is an organic solvent selected from 2-methylTHF, acetonitrile, isopropyl acetate, dichloromethane, THF, DMF, NMP, dichloromethane or a mixture thereof; preferably 2-methylTHF and acetonitrile.

[0039] In aspect 20 of the present invention, the present invention provides a method as described in aspect 3, wherein the method is carried out in the absence of a catalyst or in the presence of a metal catalyst selected from iron, gold or palladium catalysts.

[0040] In aspect 21 of the present invention, the present invention provides a method as described in aspect 20, wherein the method is carried out in the presence of a metal catalyst, wherein the catalyst is iron (III) chloride hexahydrate.

[0041] In aspect 22 of the present invention, the present invention provides a method as described in aspect 3, wherein the base is sodium bisulfite.

[0042] In aspect 23 of the present invention, the present invention provides a method as described in aspect 3, wherein the elevated temperature is at the solvent reflux temperature or 60°C to 100°C; preferably 70°C to 90°C; more preferably 70°C.

[0043] In aspect 24 of the present invention, the present invention provides a method as described in aspect 3, wherein the solvent is NMP.

[0044] In aspect 25 of the present invention, the present invention provides a method as described in aspect 4, wherein the base is a hydroxide or an amine, preferably a hydroxide.

[0045] In aspect 26 of the present invention, the present invention provides a method as described in aspect 25, wherein the base is potassium hydroxide or diisopropylethylamine; preferably potassium hydroxide.

[0046] In aspect 27 of the present invention, the present invention provides a method as described in aspect 4, wherein the solvent is a polar aprotic solvent selected from NMP, DMAC, DMF or DMSO; preferably NMP.

[0047] In aspect 28 of the present invention, the present invention provides a method as described in aspect 4, wherein the elevated temperature is at the solvent reflux temperature or 80°C to 140°C; preferably 100°C to 140°C; more preferably 120°C.

[0048] In aspect 29 of the present invention, the present invention provides the method as described in aspect 4, wherein the compound 5 is crystallized by adding an acid.

[0049] In aspect 30 of the present invention, the present invention provides a method as described in aspect 29, wherein the acid is phosphoric acid.

[0050] In aspect 31 of the present invention, the present invention provides a method as described in aspect 5, wherein the base is an amine or a hydroxide, preferably an amine.

[0051] In aspect 32 of the present invention, the present invention provides a method as described in aspect 31, wherein the base is triethylamine.

[0052] In aspect 33 of the present invention, the present invention provides a method as described in aspect 5, wherein the elevated temperature is at the solvent reflux temperature or 60°C to 100°C; preferably 60°C to 85°C; more preferably 80°C.

[0053] In aspect 34 of the present invention, the present invention provides a method as described in aspect 5, wherein the solvent is a mixture of acetonitrile and water.

[0054] In aspect 35 of the present invention, the present invention provides a method as described in aspect 9, wherein the base is a hydroxide, preferably calcium hydroxide, sodium hydroxide; more preferably calcium hydroxide.

[0055] In aspect 36 of the present invention, the present invention provides a method as described in aspect 9, wherein the solvent is C 1-6 A mixture of an alkyl alcohol and water, preferably methanol and water.

[0056] In aspect 37 of the present invention, the present invention provides a method as described in aspect 9, wherein the compound 6 is crystallized in a mixture of methanol / ethanol / water to form a hydrate compound 6a-I having the following formula:

[0057] In aspect 38 of the present invention, the present invention provides a method as described in aspect 9, wherein the temperature is 25°C to 50°C; 40°C to 50°C; preferably 50°C.

[0058] In aspect 39 of the present invention, the present invention provides a method as described in aspect 10, wherein the oxidizing agent is a peroxide or a peroxycarboxylic acid; preferably hydrogen peroxide or meta-peroxycarboxylic acid (mCPBA); more preferably hydrogen peroxide.

[0059] In aspect 40 of the present invention, the present invention provides a method as described in aspect 10, wherein the catalyst is sodium tungstate.

[0060] In aspect 41 of the present invention, the present invention provides a method as described in aspect 10, wherein the temperature is 25°C to 40°C; preferably 30°C to 35°C; more preferably 30°C.

[0061] In aspect 42 of the present invention, the present invention provides a method as described in aspect 10, wherein the solvent is a mixture of acetonitrile and water.

[0062] In aspect 43 of the present invention, the present invention provides the method as described in aspect 10, wherein the compound 12 is crystallized in acetone or a mixture of acetone and water.

[0063] In aspect 44 of the present invention, the present invention provides a method as described in aspect 10, wherein the compound 12 is not isolated and the solvent is acetonitrile.

[0064] In aspect 45 of the present invention, the present invention provides a method as described in aspect 11, wherein the

[0065] The base is a bicarbonate, carbonate, hydroxide or phosphate; preferably potassium carbonate, sodium carbonate, sodium hydroxide or potassium hydroxide; more preferably potassium carbonate.

[0066] In aspect 46 of the present invention, the present invention provides a method as described in aspect 11, wherein the base is calcium carbonate.

[0067] In aspect 47 of the present invention, the present invention provides a method as described in aspect 11, wherein the solvent is an alcohol, preferably methanol.

[0068] In aspect 48 of the present invention, the present invention provides a method as described in aspect 11, wherein the temperature is at the reflux temperature of the solvent or 70°C to 100°C; preferably 75°C to 90°C; more preferably 82°C.

[0069] In aspect 49 of the present invention, the present invention provides a method as described in any one of aspects 1-5 or 9-48, further comprising reacting the compound 1 with an acid HA in a solvent to form a pharmaceutically acceptable salt of the compound 1 having the following formula:

[0070]

[0071] In aspect 50 of the present invention, the present invention provides a method as described in aspect 49, wherein the acid HX is HCl, methanesulfonic acid or p-toluenesulfonic acid.

[0072] In aspect 51 of the present invention, the present invention provides a method as described in aspect 49, wherein the acid HX is HCl in DMSO.

[0073] In aspect 52 of the present invention, the present invention provides a method as described in aspect 49, wherein the solvent is water.

[0074] In aspect 53 of the present invention, the present invention provides a method as described in any one of aspects 1-5 or 9-52, wherein the PG is benzyl.

[0075] In aspect 54 of the present invention, the present invention provides compound 6 having the following chemical structure:

[0076]

[0077] wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; M is a metal, including a monovalent metal, a divalent metal or a trivalent metal; preferably M is a monovalent metal or a divalent metal; more preferably M is Na, Ca or Zn; most preferably M is Ca; and n is an integer selected from 1, 2 or 3; preferably n is 1 or 2; more preferably n is 2; or its solid form.

[0078] In aspect 55 of the present invention, the present invention provides a compound as described in aspect 54, wherein PG is benzyl, M is calcium, and n is 2 (compound 6a), the compound having the structure or a solid form thereof.

[0079] In aspect 56 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 55, which is crystalline or amorphous.

[0080] In aspect 57 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 55, which is a hydrate of compound 6a having the following formula: The compound contains 4 / 3 water molecules and is crystalline.

[0081] In aspect 58 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 55, which is a crystalline form 1 of the hydrate of the compound 6a (compound 6a-I), further characterized in that it has XRPD spectrum peaks at 4.2, 8.2 and 12.2±0.2°2θ using Cu Kα radiation.

[0082] In aspect 59 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 58, which is the crystalline form 1 of the compound 6a-I as described in aspect 58, further characterized in that it has XRPD spectrum peaks at 13.6, 14.2, 18.3, 19.5, 20.6, 20.9 and 22.9±0.2°2θ using Cu Kα radiation.

[0083] In aspect 60 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 59, which is the crystalline compound 6a-I as described in aspect 59, further characterized in that it has XRPD spectrum peaks at 16.2, 16.7, 19.2, 21.4, 23.9, 24.4, 24.7, 25.5, 27.6, 28.1, 30.3, 33.3 and 36.6±0.2°2θ using Cu Kα radiation.

[0084] In aspect 61 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 60, which is substantially as follows Figure 1 Shown is the XRPD pattern of crystalline compound 6a-I.

[0085] In aspect 62 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 58, which is a crystalline compound 6a-I having the following endothermic transitions: a first endothermic transition at 124.96°C to 130.96°C; and a second endothermic transition at 256.11°C to 262.11°C; as described by substantially Figure 2 The shown are measured by differential scanning calorimetry.

[0086] In aspect 63 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 58, which is a crystalline compound 6a-I, wherein the first endothermic transition is at 127.96°C±3°C; and the second endothermic transition is at 259.11°C±3°C.

[0087] In aspect 64 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 58, which is substantially as follows Figure 3 Thermogravimetric analysis (TGA) of crystalline compound 6a-I is shown.

[0088] In aspect 65 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 58, which is stable and has low hygroscopicity. In one embodiment, the solid form stability can be identified by the absence of change in the crystalline form and substantially the same XRPD peaks shown in the XRPD peaks of the crystallized sample before and after DVS. In another embodiment, the low hygroscopicity characteristics of the crystallized sample can be shown by measuring the mass of the sample at the beginning and end of the DVS experiment, wherein the calculated mass change is between 0.10% and 0.20%; preferably 0.15%.

[0089] In aspect 66 of the present invention, the present invention provides a solid form of the compound 6a according to aspect 58, which is substantially as follows Figure 4 The single crystal structure of crystalline compound 6a-I is shown.

[0090] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which the present disclosure belongs. Methods and materials for the present disclosure are described herein; other suitable methods and materials known in the art may also be used. The materials, methods and embodiments are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries and other references mentioned herein in the brief description of the present invention and in the following sections are incorporated herein by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail. Other features and advantages of the present disclosure will become clear from the following additional descriptions, embodiments and claims set forth above. BRIEF DESCRIPTION OF THE DRAWINGS

[0091] Figure 1 Depicted are (1) X-ray powder diffraction ("XRPD") spectra of crystalline Compound 6a-I before and after humidity stress measured on dynamic vapor sorption (DVS); and (2) simulated XRPD spectra of the single crystal structure of Compound 6a-I.

[0092] Figure 2 Depicted is a differential scanning calorimetry (DSC) thermogram of crystalline Compound 6a-I.

[0093] Figure 3 Thermogravimetric analysis (TGA) of crystalline Compound 6a-I is depicted.

[0094] Figure 4 The single crystal structure of crystalline compound 6a-I is depicted. DETAILED DESCRIPTION

[0095] definition

[0096] The following definitions should further assist in understanding the terms as used herein and the scope of the invention described herein.

[0097] The term "C x-y "Alkyl" refers to a substituted or unsubstituted saturated hydrocarbon group, including straight chain alkyl and branched chain alkyl groups containing from x to y carbons in the chain.

[0098] The term "haloalkyl" refers to an alkyl group in which at least one hydrogen atom is replaced by a halogen (eg, fluorine, chlorine, bromine, iodine), for example, CH2F, CHF2, trifluoromethyl and 2,2,2-trifluoroethyl.

[0099] The term "comprising" is intended to be open-ended, including the indicated components but not excluding other elements.

[0100] The term "equivalent" is intended to mean molar equivalents, as commonly understood by those skilled in the art.

[0101] The term "pharmaceutically acceptable salt" refers to relatively non-toxic inorganic and organic acid addition salts of compound 5 of the present invention. The nature of the salt is not critical, as long as it is pharmaceutically acceptable. These salts can be prepared in situ during the final separation and purification of one or more compounds, or by reacting the purified compound in its free base form with a suitable organic or inorganic acid alone and separating the salt thus formed. Suitable pharmaceutically acceptable acid addition salts of the compound can be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid, and phosphoric acid. Examples of organic acids include, but are not limited to, aliphatic, alicyclic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic acids, examples of which are formic, acetic, adipic, butyric, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, ethanedisulfonic, benzenesulfonic , pantothenic acid, 2-hydroxyethanesulfonic acid, toluenesulfonic acid, sulfanilic acid, cyclohexylaminosulfonic acid, camphoric acid, camphorsulfonic acid, digluconic acid, cyclopentanepropionic acid, dodecanesulfonic acid, glucoheptonic acid, glycerophosphonic acid, heptanoic acid, hexanoic acid, 2-hydroxy-ethanesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, palmic acid, pectic acid, persulfuric acid, 2-phenylpropionic acid, picric acid, pivalic acid, succinic acid, tartaric acid, thiocyanic acid, methanesulfonic acid, undecanoic acid, stearic acid, alginic acid, β-hydroxybutyric acid, salicylic acid, mucic acid, and galacturonic acid (see, e.g., Berge et al., (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66: 1-19).

[0102] As used herein, the term "hydroxy protecting group" means a protecting group suitable for preventing undesirable reactions on a hydroxy group. Representative hydroxy protecting groups include, but are not limited to, silyl, including tri(C 1-6 alkyl) silyl, such as trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBS), etc.; esters (acyl groups), including C 1-6Alkanoyl groups such as formyl, acetyl, etc.; arylmethyl groups such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), diphenylmethyl (diphenylmethyl, DPM), etc. Many protecting groups and their introduction and removal are described in TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd Edition, Wiley, New York.

[0103] As used herein, the term "metal" refers to a "monovalent metal", "divalent metal" or "trivalent metal".

[0104] As used herein, the term "monovalent metal" refers to a metal that is part of an ionic bond, wherein the metal forms an ion with a charge of +1. Examples of monovalent metals are metals of Group 1 of the IUPAC periodic table (thus excluding hydrogen). Preferred monovalent metals are Na, K and Li.

[0105] As used herein, the term "divalent metal" refers to a metal that is part of an ionic bond, wherein the metal forms an ion with a charge of +2. Examples of divalent metals are metals of Group 2 of the IUPAC periodic table. Preferred divalent metals are Mg, Zn or Ca.

[0106] As used herein, the term "trivalent metal" refers to a metal that is part of an ionic bond, wherein the metal forms an ion with a charge of +3. Examples of trivalent metals are Al and Fe.

[0107] As used herein, the term "solvent" includes an "aqueous solvent" or an "organic solvent".

[0108] As used herein, the term "aqueous solvent" means a solvent containing water.

[0109] As used herein, the term "organic solvent" refers to an organic molecule that is capable of dissolving another substance (ie, a solute). The organic solvent may be a liquid at room temperature. Examples of organic solvents that can be used in the present invention include, but are not limited to, hydrocarbon solvents (e.g., n-pentane, n-hexane, n-heptane, n-octane, cyclohexane, methylcyclohexane, decalin, etc.), which also include aromatic hydrocarbon solvents (e.g., benzene, toluene, o-xylene, m-xylene and p-xylene), halogenated hydrocarbon solvents (e.g., carbon tetrachloride, 1,2-dichloroethane, dichloromethane, chloroform, etc.), ester solvents (e.g., ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, ethyl malonate, etc.), ketone solvents (e.g., acetone, methyl ethyl ketone or 2-butanone, methyl isobutyl ketone, cyclohexanone, cyclopentanone, 3-pentanone, etc.), ether solvents (e.g., diethyl ether, dipropyl ether, diphenyl ether, isopropyl ether, tert-butyl methyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dihydrofuran, etc.), and ether solvents (e.g., diethyl ether, dipropyl ether, diphenyl ether, isopropyl ether, tert-butyl methyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dihydrofuran, etc.). , methyl phenyl ether or anisole, etc.), amine solvents (e.g., propylamine, diethylamine, triethylamine, aniline, pyridine), alcohol solvents (e.g., methanol, ethanol, isopropanol, 1-propanol, 2-methyl-1-propanol, 1-butanol, 2-butanol, 1-pentanol, 3-methyl-1-butanol, tert-butyl alcohol, 1-octanol, benzyl alcohol, phenol, trifluoroethanol, glycerol, ethylene glycol, propylene glycol, meta-cresol, etc.), acid solvents (e.g., acetic acid, hexanoic acid, etc.), nitrobenzene, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, acetonitrile, propionitrile, butyronitrile, silicone solvents (e.g., silicone oil, polysiloxane, cyclosilicone). In some embodiments, the organic solvent can be formed by a combination of two or more organic solvents.

[0110] As used herein, the term "polar solvent" means a solvent having a dielectric constant of at least 3, which is the ratio of the capacitance of a capacitor filled with the solvent to the capacitance of an evacuated capacitor at 20° C. to 25° C. The dielectric constant values ​​of the solvents are disclosed in Vogel's Textbook of Practical Organic Chemistry, 5th edition, Appendix 5. Examples of polar solvents are dichloromethane, tetrahydrofuran, ester solvents (e.g., ethyl formate, methyl acetate, ethyl acetate, ethyl malonate, etc.), ketone solvents (e.g., acetone, methyl ethyl ketone or 2-butanone, cyclohexanone, cyclopentanone, 3-pentanone, etc.), amine solvents (e.g., propylamine, diethylamine, triethylamine, aniline, pyridine), alcohol solvents (e.g., methanol, ethanol, isopropanol, 1-propanol, 1-butanol, 1-octanol, benzyl alcohol, phenol, trifluoroethanol, glycerol, ethylene glycol, propylene glycol, m-cresol, etc.), acid solvents (e.g., acetic acid, hexanoic acid, etc.), nitrobenzene, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, acetonitrile, propionitrile, butyronitrile and silicone solvents (e.g., silicone oil, polysiloxane, cyclosilicone).

[0111] As used herein, the term "alcohol" refers to a hydrocarbon derivative in which one or more hydrogen atoms are replaced by an -OH group (referred to as a hydroxyl group). Suitable alcohols for use in the present invention include linear, cyclic or branched C 1-6 Alkyl alcohols and any mixtures thereof. It also includes commercially available alcohols. Examples of alcohols are methanol, ethanol, isopropanol, 1-propanol, 1-butanol, 1-pentanol, 3-methyl-1-butanol, tert-butanol, 1-octanol, benzyl alcohol and phenol.

[0112] As used herein, the term "benzyl" refers to a substituent group having the structure C6H5CH2-.

[0113] As used herein, the term "reflux" refers to the temperature at which the reaction mixture boils, depending on the solvent used in the reaction. For example, when water is used as the solvent, the reflux temperature is as high as 100°C.

[0114] As used herein, the term "oxidant" refers to a substance that can act as an electron acceptor to oxidize other substances. Commonly used oxidants include oxygen (O2); ozone (O3); hydrogen peroxide (H2O2), including other inorganic peroxides or Fenton's reagent; organic peroxides, such as peroxycarboxylic acids having the formula RCO3H, where R is an alkyl or aryl group, including peracetic acid or meta-chloroperbenzoic acid (mCPBA); fluorine (F2), chlorine (Cl2) or other halogens; nitric acid (HNO3) or nitrate compounds; sulfuric acid (H2SO4); peroxydisulfuric acid (H2S2O8); peroxymonosulfuric acid (H2SO5); hypochlorites, chlorites, chlorates, perchlorates or other similar halogen compounds, including household bleach (na clo); hexavalent chromium compounds such as chromic acid, dichromic acid, chromium trioxide, pyridinium chlorochromate (PCC), or chromate / dichromate compounds; permanganate compounds such as potassium permanganate (KMNO4); sodium perborate; nitrous oxide (N2O), nitrogen dioxide / nitrogen tetroxide (NO2 / N2O4); potassium nitrate (KNO3); sodium bismuthate (NaBiO3); cerium (IV) compounds such as ammonium cerium nitrate or cerium sulfate; lead dioxide (PbO2); or sodium dichromate (Na2Cr2O7).

[0115] As used herein, the term "substituted" refers to a substituent replacing a portion of hydrogen on one or more non-hydrogen atoms in a molecule. It will be understood by those skilled in the art that "substitution" or "substituted" includes the following implicit conditions: such substitution is based on the allowed valence of the substituted atom and the substituent, and the substitution produces a stable compound, for example, the compound does not spontaneously undergo transformation, such as by rearrangement, cyclization, elimination, etc. As used herein, the term "substituted" is intended to include all allowed substituents of an organic compound. In a broad sense, allowed substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. For appropriate organic compounds, allowed substituents can be one or more and are the same or different. For the purposes of this disclosure, a heteroatom (such as nitrogen) can have a hydrogen substituent and / or any allowed substituent of an organic compound described herein, and the substituent will satisfy the valence of the heteroatom. Substituents may include, for example, halogen, hydroxy, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acyl), thiocarbonyl (e.g., thioester, thioacetate or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphite, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfonamide, sulfonamido, sulfonyl, heterocyclyl, aralkyl or aromatic or heteroaromatic moieties. It will be appreciated by those skilled in the art that the moieties substituted on the hydrocarbon chain may themselves be substituted if appropriate and if valence permits.

[0116] As used herein, the term "continuous process" or "continuous" refers to a manufacturing process that uses one or more reagent or product streams that flow continuously from one unit operation to the next, with all operations occurring simultaneously when the system is in a steady state.

[0117] The term "batch process" or "batch" refers to a manufacturing process in which a given unit operation must be run to completion before the next unit operation can begin. Typically, the product of the previous unit operation is separated or purified before being used as the starting material for the next unit operation.

[0118] General Synthesis and Representative Examples of the Invention

[0119] The following abbreviations used throughout the specification including the general schemes and examples have the following meanings:

[0120] DIPEA N,N-Diisopropylethylamine

[0121] DMF Dimethylformamide

[0122] DMSO Dimethyl sulfoxide

[0123] eq, equiv equivalent (mole)

[0124] EtOAc Ethyl acetate

[0125] g, gm grams

[0126] GC Gas chromatography

[0127] HPLC High Performance Liquid Chromatography

[0128] IPAc Isopropyl acetate

[0129] MeCN Acetonitrile

[0130] MeOH Methanol

[0131] 2-MeTHF 2-Methyltetrahydrofuran

[0132] mL, ml milliliter

[0133] mpk, mg / kg milligrams per kilogram

[0134] NaCl Sodium chloride

[0135] NaOH Sodium hydroxide

[0136] RT, rt room temperature

[0137] THF Tetrahydrofuran

[0138] Materials and Methods

[0139] Unless specified, commercially available reagents were used as received without further purification.

[0140] PANalytical X'Pert PRO Diffractometer - Reflection Geometry

[0141] Unless stated to the contrary, XRPD spectra were collected using a PANalytical X'Pert PRO diffractometer.

[0142] The single crystal structure was determined using XtaLAB Synergy, Dualflex, and HyPix diffractometers.

[0143] Differential scanning calorimetry (DSC) was performed using a Mettler-Toledo DSC3+ differential scanning calorimeter. Tau hysteresis adjustment was performed with indium, tin, and zinc. Temperature and enthalpy were adjusted with octane, phenyl salicylate, indium, tin, and zinc. The adjustment was then verified with octane, phenyl salicylate, indium, tin, and zinc. The sample was placed in an airtightly sealed aluminum DSC pan, and the weight was accurately recorded. The pan cover was pierced by a tool and then inserted into the DSC cell for analysis. A weighed aluminum pan configured as a sample pan was placed on the reference side of the cell.

[0144] Alternatively, Differential Scanning Calorimetry (DSC) analysis was also performed on a TA Instruments Q and Discovery series calorimeter at 50 ml / min under dry nitrogen in an aluminum pan at 10°C / min from 25°C to 250°C to 350°C.

[0145] Thermogravimetric analysis (TGA) was performed on a TA Instruments Q and Discovery series analyzer at 25 ml / min in platinum pans at 10 °C / min from ambient temperature between 250 °C and 350 °C under dry nitrogen.

[0146] Moisture sorption data were collected using a DVS Endeavour. A sample size of approximately 30 mg was used. The temperature was 25°C. The relative humidity (RH) was maintained at 80% for 24 hours. The mass was recorded at the beginning and end of the experiment.

[0147] Solution proton NMR spectra were collected at 25° C. using a Varian UNITY INOVA-400 spectrometer by Spectral Data Services (SSCI) in Champaign, IL. Unless otherwise stated, samples were dissolved in DMSO-d6. In some cases, solution NMR spectra were also collected at SSCI using an Agilent DD2-400 spectrometer using deuterated DMSO or methanol.

[0148] General Embodiments of the Invention

[0149] The present inventors have developed a novel and improved method of the present invention for preparing compound 1 and its pharmaceutically acceptable salts (preferably its HCl salt (compound 1a)) from the following five key starting materials / intermediate compounds: compound 6, compound 7, compound 8, compound 9 and compound 10. The novel synthetic route of compound 1 and the pharmaceutically acceptable salt of compound 1 of the present invention adopts a late amide coupling strategy. The method of the present invention utilizes the inherent reactivity of 2-fluoro-4-nitrobenzoic acid (compound 8 or its salt) to provide a hydroxyl-protected (preferably benzyl ether-protected) compound 2 through continuous CN and SN bond formation, which undergoes deprotection to form a free base compound 1. Compound 1 is then reacted with acid HA to form a salt to obtain a pharmaceutically acceptable salt of compound 1.

[0150]

[0151] Scheme A: Steps 1-3 Preparation of compound 6 and its solid form.

[0152] Scheme A depicts steps 1-3 for preparing compound 6 of the present invention. Compound 6 is a novel calcium sulfinate (sulfinic acid) salt compound, and Scheme A describes a new reliable route for preparing calcium sulfinate salts. Literature routes for preparing sulfinates are known, for example: (a) Liang et al., "Recent Advances in the Synthesis and Direct Application of Sulfinate Salts", Eur. J. Org. Chem. 2020, 4664-4676; (b) Gianatassio et al., "Simple Sulfinate Synthesis Enables C-HTrifluoromethyl-cyclopropanation", Angew. Chem. Int. Ed., 2014, 53, 9851-9855; (c) Day et al., "Benzothiazole Sulfinate: A Sulfinic Acid Transfer Reagent under Oxidation-Free Conditions", Org. Lett. 2017, 19, 3819-3822; (d) Cochran et al., "Development of a Commercial Process To Prepare AMG 232 Using a Green Ozonolysis-Pinnick Tandem Transformation”, J. Org. Chem. 2019, 84, 4763-4779; and (e) O'Hara et al., “Preparation and purification of zinc sulfinate reagents for drug discovery”, doi: 10.1038 / nprot.2013.059; provide convenient access to the sodium salt; however, the most common route uses (a) reduction of the sulfonyl chloride, typically with sodium sulfite or sodium bissulfonyl chloride, as described in Scheme B below, which represents a processing challenge:

[0153]

[0154] Scheme B: Prior art literature method for preparing sulfinate RS02M; wherein R is an organic functional group; each Het and Ar is as defined above; and M is a metal.

[0155] Using these literature processes, the sodium sulfinate product may be highly hygroscopic or may be found to have undesirable physical properties. The inventive process presented herein produces metal sulfinates, such as zinc sulfinate, sodium sulfinate, and calcium sulfinate salts, having improved physical properties and stability.

[0156] In Scheme A, step 1, a compound 13 having the formula LG4-SH (wherein LG4 is an organic leaving group, preferably an unsubstituted benzothiazolyl) is reacted with a compound 14 having the formula PG-O-CH2CH2-LG3 in the presence of a base in a solvent to form a compound 12 having the formula LG4-O-CH2CH2-OPG. Preferably, the compound 13 has the formula Preferably, the compound 14 has the formula wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 LG3 is a leaving group; preferably LG3 is halogen, more preferably fluorine, chlorine or bromine, more preferably bromine. Preferably, the compound 12 has the formula wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 Preferably, the base is a bicarbonate, a carbonate, a hydroxide or a phosphate; preferably potassium carbonate, sodium carbonate, sodium hydroxide or potassium hydroxide; more preferably potassium carbonate or calcium carbonate; more preferably potassium carbonate. Preferably, the solvent is an alcohol, more preferably methanol. Preferably, the reaction is carried out at a temperature of the solvent reflux temperature or 70°C to 100°C; preferably 75°C to 90°C; more preferably 82°C.

[0157] In an alternative preferred embodiment, step 1 is carried out in the presence of potassium carbonate base, producing a steady stream of said compound 12 in acetonitrile.

[0158] In Scheme A, step 2, compound 12 as defined above is reacted with an oxidizing agent in the presence of a catalyst in a solvent at a slightly elevated temperature to form compound 11. Preferably, the compound 11 has the formula wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6Alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl. Examples of the oxidizing agent are peroxides or peroxycarboxylic acids; preferably hydrogen peroxide or meta-peroxycarboxylic acids; more preferably hydrogen peroxide. An example of the catalyst is sodium tungstate. Preferably, the reaction is carried out at a temperature of 25°C to 40°C; preferably 30°C to 35°C; more preferably 30°C. Preferably, the solvent is a mixture of acetonitrile and water.

[0159] In one embodiment of step 2, the compound 12 is crystallized as a crystalline solid in acetone or a mixture of acetone and water.

[0160] In an alternative embodiment of step 2, the compound 12 is not isolated from step 1 and the solvent is acetonitrile. The subsequent oxidation of the compound 12 is carried out with sodium tungstate as catalyst and hydrogen peroxide as stoichiometric oxidant.

[0161] Step 2 is a batch reaction process and faces safety issues when using H2O2, which requires appropriate safety controls. In order to overcome the safety issues, the inventors developed a continuous process during scale-up production. There were two major challenges during the initial continuous process development, one was the poor solubility of compound 12, and the other was the slow conversion rate of the oxidation reaction of compound 12. In order to overcome the solubility problem, the inventors further screened the combined solvent volume in the continuous process and successfully used the continuous process for scale-up production, which improved the efficiency and safety of step 2 production. H2O2 was adjusted to 30% w / w, 3.0 equivalents, the pH range was maintained at 3-4, the addition of H2O2 was optimized to 3-4 parts, and 33% NaHSO3 solution was used as a quenching solvent.

[0162] In Scheme A, step 3, compound 11 as defined above is reacted with a base in a polar solvent at a moderately elevated temperature to form the wherein PG is benzyl, M is calcium, and n is 2. Preferably, compound 6 has the structure More preferably, compound 6a has the structure Examples of the base are hydroxides, preferably calcium hydroxide, sodium hydroxide; more preferably calcium hydroxide. Examples of the solvent are C 1-6A mixture of an alkyl alcohol and water, preferably methanol and water; or methanol. In one embodiment, the compound 6 product is crystalline, preferably compound 6 is crystallized in a mixture of methanol / ethanol / water to form compound 6a-I. Preferably, the reaction is carried out at a temperature of 25°C to 50°C; 40°C to 50°C; preferably 50°C. Most preferably, the cleavage of the benzothiazole leaving group is accomplished using calcium hydroxide in aqueous methanol to produce a calcium sulfinate compound 6, which is separated into a crystalline hydrate form via crystallization with acetone. It was found that water is critical because it can accelerate the mass transfer of calcium hydroxide and is present in the lattice of the crystal structure of the compound 6a. The crystalline product of compound 6a is a crystalline hydrate compound (compound 6a-I) containing about 1 water molecule, more specifically and preferably 4 / 3 water molecules or about 1.33 water molecules.

[0163]

[0164] Scheme B: Steps 4-5 Preparation of compound 3.

[0165] Scheme B depicts step 4 to step 5 of the present invention. In step 4 of scheme B, the method of the present invention utilizes a base-mediated aromatic substitution reaction of compound 7 and compound 8 to produce a key intermediate compound 5. The synthesis of compound 5 is an aromatic substitution (SNAr) reaction, which is preferably carried out by treating compound 8 (wherein LG1 is a leaving group, preferably a halogen, more preferably chlorine or fluorine, most preferably fluorine) and compound 7 (wherein X1 is a halide, preferably a chloride or bromide, more preferably a chloride) in NMP with KOH under elevated reaction conditions. The SNAr reaction is carried out with high conversion, wherein the desired product is directly isolated after adjusting the pH with aqueous phosphoric acid and precipitating with water to obtain a compound 5 product as a crystalline solid.

[0166] In Scheme B, step 5, compound 5 and compound 6; or its hydrate (compound 6a-1) of the subsequent nitroaromatic / sulfinate coupling leads to the formation of compound 3 as a key intermediate compound. The synthesis of compound 3 is preferably carried out by the iron-catalyzed coupling of compound 5 and compound 6 or its hydrate (compound 6a-1) in NMP with sodium bisulfite as a stoichiometric reducing agent. The nitroaromatic / sulfinate coupling reaction is carried out with high conversion and good chemical selectivity to the desired sulfonamide product. The product is preferably separated after aqueous post-treatment to remove inorganic impurities. The product solvent is preferably exchanged into THF and crystallized from MTBE anti-solvent crystallization to obtain the compound 3 product as a crystalline solid.

[0167]

[0168] Scheme C: Step 6 Preparation of Compound 4

[0169] Scheme C depicts step 6 of the present invention. In step 6, compound 4 is synthesized by an acid-mediated aromatic substitution reaction of compound 9 and compound 10. The synthesis of compound 4 has been improved from the synthesis of compound 4 previously disclosed in U.S. Pat. No. 11 / 236,069. In the improved method, preferably, the compound 4 product is generated by an acid-catalyzed SNAr reaction of compound 9 and compound 10 in a solvent mixture of tert-butyl alcohol: toluene under elevated reaction conditions, wherein X2 is a chloride. The SNAr reaction is carried out at a high conversion rate, and the desired product is isolated after salt destruction with aqueous NaOH and crystallization from a toluene / n-heptane solvent system to obtain a product as a crystalline solid.

[0170]

[0171] Scheme D: Steps 7-8 Preparation of Compound 1

[0172] Scheme D depicts steps 7-8 of the present invention for preparing the free base form of compound 1. In step 7, late fragments of compound 3 and compound 4 are coupled under amide coupling conditions to generate the penultimate intermediate compound 2 as a crystalline intermediate. The synthesis of compound 2 is preferably carried out by chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH)-mediated amide coupling of compound 3 and compound 4 in 2-methylTHF, acetonitrile, isopropyl acetate, dichloromethane, THF, NMP or mixtures thereof; preferably 2-methylTHF and acetonitrile in the presence of a base, preferably 2,4,6-trimethylpyridine (collidine) under elevated reaction conditions. The amide coupling is carried out with high chemoselectivity using 2,4,6-trimethylpyridine as a base to afford the desired amide compound 2 product in high chemical yield after aqueous workup and crystallization from 2-MeTHF / isopropylamine to afford the product as a crystalline solid.

[0173] In step 8, Pd-catalyzed hydrogenation of compound 2 removes the benzyl ether protecting group, resulting in the formation of compound 1 as a crystalline free base compound. In a preferred embodiment, the synthesis of compound 2 is carried out by hydrogenating compound 2 in an acetic acid / water mixture in the presence of Pd / C as a heterogeneous catalyst. The hydrogenation is carried out with high conversion, and product isolation is achieved after filtration of the catalyst and addition of an anti-solvent of 1-propanol to obtain compound 1 product as a crystalline solid.

[0174]

[0175] Scheme E: Step 9 Preparation of a Pharmaceutically Acceptable Salt of Compound 1

[0176] Scheme E depicts step 9 of the present invention. In step 9, salification is performed by treating the crystalline free base compound 1 with HCl to generate the HCl salt of compound 1 (compound 1a), wherein optional grinding can be performed to reduce the particle size distribution (PSD). In a preferred embodiment, the synthesis of compound 1a is performed by treating a solution of compound 1 in DMSO with aqueous HCl. The product is precipitated via the addition of antisolvent water to provide a product that is a crystalline solid. Grinding can be performed to reduce particle size. Other preferred salts of compound 1 include mesylate or tosylate.

[0177] Representative Embodiments of the Invention

[0178] The following syntheses are representative examples of the invention and are not intended to be construed as limiting the scope of the invention.

[0179] Example 1: Preparation of 2-((2-(Benzyloxy)ethyl)thio)benzo[d]thiazole

[0180]

[0181] To a vial equipped with magnetic stirring was added mercaptobenzothiazole (2.8 kg, 1.00 equiv), potassium carbonate (3.5 kg, 1.5 equiv) and anhydrous acetonitrile (22 L). To the stirred solution was added ((2-bromoethoxy)methyl)benzene (3.9 L, 1.00 equiv) dropwise. The solution was stirred at 82 °C for 18 hours. The mixture was filtered on a medium porosity glass sinter funnel to remove solids, and the filtrate was concentrated to give the product, 2-((2-(benzyloxy)ethyl)thio)benzo[d]thiazole, as an orange oil, which was used in the next step without further purification.

[0182] Example 2: Preparation of 2-((2-(Benzyloxy)ethyl)sulfonyl)benzo[d]thiazole

[0183]

[0184] The three solutions in the separate plug flow reactors were combined in a mixer and circulated in a single plug flow reactor at 50°C with a residence time of 15 minutes. The three solutions were prepared as follows: (i) 2-((2-(benzyloxy)ethyl)thio)benzo[d]thiazole (5.0 kg, 1.0 eq.), (ii) Na2WO4 (245 g, 0.05 eq.), water (2.5 L), phosphoric acid (85%, 125 g, 0.025 eq.), and (iii) aqueous H2O2 (1.8 kg of a 35% w / w solution, 4.5 eq.). The solutions were passed through a continuously stirred tank reactor at 60°C for 10 min, followed by another plug flow reactor at 65°C for 15 min. The mixture was cooled to 20°C and 55 L of water was added. Aqueous NaHSO3 (10 L of a 33% w / w solution, 1.9 eq.) was added while maintaining the temperature at 20°C. The mixture was filtered and the filter cake was washed twice with 15 L of water. The filter cake was washed with 15 L of heptane and dried under vacuum at 40°C to give the product 2-((2-(benzyloxy)ethyl)sulfonyl)benzo[d]thiazole.

[0185] Example 3: Preparation of calcium 2-(benzyloxy)ethane-1-sulfinate and its crystalline hydrate salt

[0186]

[0187] To a mixture of 2-((2-(benzyloxy)ethyl)sulfonyl)benzo[d]thiazole (4.4 kg, 1.0 equiv) and Ca(OH)2 (98 g, 0.1 equiv) in methanol (26 L) was added Ca(OH)2 (431 g, 0.44 equiv) in 4 portions over the course of 8 hours at 50°C. The mixture was cooled to 40°C and filtered. The filter cake was washed with 18 L of methanol. The filtrate was concentrated to approximately 9 L of solution and warmed to 55°C. Water (2.2 L) was added at 55°C, and then ethanol (16.5 L). The mixture was cooled to 5°C over 4 hours and stirred at that temperature for 10 hours. The slurry was filtered, and the filter cake was washed with 22 L of ethanol. 4.4 L of methanol was added to the filter cake, and the mixture was warmed to 55°C. Water (1.1 L) was added at 55°C, and then ethanol (16.5 L) was added. The mixture was cooled to 5°C over 4 hours and stirred at that temperature for 10 hours. The slurry was filtered and the filter cake was washed with 44 L of ethanol. The filter cake was dried under vacuum at 40°C, resulting in the isolation of calcium 2-(benzyloxy)ethane-1-sulfinate as a crystalline hydrate, more specifically a 4 / 3 hydrate compound, with a yield of 72%: 1H NMR (500MHz, D2O): δ7.43 (m, 10H), 4.58 (s, 4H), 3.84 (t, 6.2Hz, 4H), 2.62 (t, 6.2Hz, 4H); 13 C NMR (125MHz, D2O): δ138.3, 129.8, 129.5, 129.4, 74.0, 65.8, 62.3. HRMS-ESI(m / z):[M] - , for [C9H 11 O3S] - Calculated value: 199.0434; measured value: 199.0429.

[0188] X-ray powder diffraction: The XRPD spectrum of crystalline compound 6a-I is shown in Figure 1 Irradiation with CuKα at 45 kV and 40 mA in a step size of 0.0334 degrees in a continuous mode from 5 to 45 degrees or from 5 to 45 degrees (2θ) at ambient temperature The sample was scanned. The incident beam path was equipped with a 0.02 radian Soller slit, a 15 mm mask, a 4 degree fixed anti-scatter slit, and a programmable divergence slit. The diffracted beam was equipped with a 0.02 radian Soller slit, a programmable anti-scatter slit, and a 0.02 mm nickel filter. The sample was prepared on a low background sample holder and placed on a rotating stage with a rotation time of 2 seconds.

[0189] Stability and hygroscopicity characteristics of crystalline compound 6a-I as shown before and after DVS XRPD experiments: Crystalline compound 6a-I was exposed to 80% relative humidity at 25°C for 24 hours using a DVS Endeser instrument. The mass was recorded at the beginning and end of the exposure. The inventors found that the starting mass was 32.3989 mg, while the ending mass was 32.4479, with a calculated mass change of 0.15%. The mass change showed that crystalline compound 6a-I absorbed 0.15% by weight of water. This shows that crystalline compound 6a-I has low hygroscopicity. After exposure to 80% relative humidity at 25°C for 24 hours, no change in the crystalline form was found, as shown in the substantially identical XRPD peaks of the crystalline samples before and after DVS (see Tables 1 and 2).

[0190] Table 1: XRPD spectrum of crystalline compound 6a-I obtained before DVS experiment.

[0191]

[0192]

[0193] Table 2: XRPD spectrum of crystalline compound 6a-I obtained after DVS experiment.

[0194]

[0195]

[0196] XPRD peak characterization: Crystalline Compound 6a-I was further characterized by an X-ray powder diffraction pattern (XPRD) and was found to be a stable polymorphic form, having peaks at 4.2, 8.2, and 12.2 ± 0.2 ° 2θ using Cu Kα radiation. Crystalline Compound 6a-I may optionally be further characterized by an X-ray powder diffraction pattern having additional peaks at 13.6, 14.2, 18.3, 19.5, 20.6, 20.9, and 22.9 ± 0.2 ° 2θ using Cu Kα radiation. Crystalline Compound 6a-I may optionally be further characterized by an X-ray powder diffraction pattern having additional peaks at 16.2, 16.7, 19.2, 21.4, 23.9, 24.4, 24.7, 25.5, 27.6, 28.1, 30.3, 33.3, and 36.6 ± 0.2 ° 2θ using Cu Kα radiation. In some embodiments, crystalline Compound 6a-1 has substantially Figure 1 X-ray powder diffraction pattern shown, where "substantially" means that the reported peaks can vary by ±0.2°. Those skilled in the art know that in the field of XRPD, while the relative peak heights in the spectrum depend on a variety of factors, such as sample preparation and instrument geometry, the peak positions are relatively insensitive to experimental details.

[0197] The crystalline compound 6a-I was obtained. Differential Scanning Calorimetry (DSC) Thermogram. The DSC curve shows an endothermic transition at 127.96°C ± 3°C. Thus, in some embodiments, the crystalline compound 6a-I can be characterized by a DSC thermogram having a transition endotherm starting at 124.96°C to 130.96°C. For example, in some embodiments, the crystalline compound 6a-I is characterized by Figure 2 DSC shown.

[0198] Thermogravimetric analysis (TGA): Crystalline Compound 6a-I can also be characterized by TGA. Thus, crystalline Compound 6a-I can be characterized by a weight loss in the range of about 4.5% to about 4.7% at an onset temperature of 124.96°C to 130.96°C. For example, crystalline Compound 6a-I can be characterized by a weight loss of about 4.62% at up to about 127.96°C. In some embodiments, crystalline Compound 6a-I has substantially Figure 3 Thermogravimetric analysis depicted in , where "substantially" means that the reported TGA features can vary by ± 3°C.

[0199] Dynamic Vapor Sorption (DVS):Crystalline Compound 6a-I can be characterized by a DVS moisture sorption curve. XPRD peak characterization before and after DVS showed that crystalline Compound 6a-I has a stable crystalline polymorphic form and has low hygroscopicity, as the weight loss corresponding to water loss is only 0.15%.

[0200] Single crystal experiment: Colorless needle-shaped single crystals of compound 6a-I were used. The size of the selected crystals was 0.23 × 0.09 × 0.01 mm 3 A suitable crystal was prepared and mounted on a mikrotron with paratone oil on an XtaLAB Synergy, Dualflex, HyPix diffractometer. The crystal was kept at steady state T = 100.00 (10) K during data collection. The structure was solved using the dual method and with the ShelXT 2018 / 2 (Sheldrick, 2018) solution program by using Olex2 1.5-α (Dolomanov et al., 2009) as a graphical interface. F was analyzed using ShelXL 2018 / 3 (Sheldrick, 2015). 2 The model was improved by performing full matrix least squares minimization. Table 3 shows the Figure 4 Summary of crystallographic data for crystalline compound 6a-I shown.

[0201] Table 3: Summary of X-ray single crystallography data of crystalline compound 6a-I:

[0202]

[0203]

[0204] Example 4: Preparation of 4-nitro-2-(6-azaspiro[2.5]oct-6-yl)benzoic acid

[0205]

[0206] 2-Fluoro-4-nitrobenzoic acid (150 g, 1.0 eq.), 6-azaspiro[2.5]octane hydrochloride (131.6 g, 1.10 eq.) and NMP (900 ml) were added to a 2 L container. The resulting mixture was stirred at 20 ° C for 30 minutes. KOH (112.3 g, 2.10 eq.) was added and the mixture was heated to 120 ° C. The mixture was stirred at 120 ° C for 16 hours and cooled to 90 ° C. An aqueous solution of H3PO4 (0.6 eq. H3PO4 in 750 ml of water) was added at 90 ° C within 2 hours. After addition, the suspension was stirred at 90 ° C for 1 hour, cooled to 20 ° C within 5 hours, and stirred at 20 ° C for 5 hours. The product was isolated by filtration, washed with a 1 / 1 mixture of NMP / water (500 mL), and then washed with water (500 mL). The filter cake was dried under vacuum to give 4-nitro-2-(6-azaspiro[2.5]oct-6-yl)benzoic acid as a crystalline solid in 90% yield. 1 H NMR (500MHz, dmso-d6): δ15.46(bs,1H),8.15(bs,1H),7.98(bd,8.6Hz,1H),7.94(bd,8.9Hz,1H),3.17(m,4H),1.53(m,4H),0.39(s,4H); 13 C NMR(125MHz,dmso-d6): δ166.8,151.6,149.8,131.8,130.5,117.7,115.6,52.1,34.4,16.6,11.2; HRMS-ESI(m / z):[M+H] + , for [C 14 H 16 N2O4+H] + Calculated value: 277.1183; measured value: 277.1183.

[0207] Example 5: Preparation of 4-((2-(benzyloxy)ethyl)sulfonylamino)-2-(6-azaspiro[2.5]oct-6-yl)benzoic acid preparation

[0208]

[0209] 4-Nitro-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid (150 g, 1.0 eq), calcium 2-(benzyloxy)ethane-1-sulfinate (143 g, 0.6 eq), NaHSO (226 g, 4.0 eq), FeCl 6H O (14.5 g, 0.1 eq) were added to the reaction vessel. NMP (750 mL) was added. The mixture was warmed to 70° C. over 1 hour and stirred at that temperature for 8 hours. The batch was cooled to 50° C. and diluted with THF (2.25 L). EGTA aqueous solution (20%) was added, adjusted to pH 7 with 10 M NaOH (1.05 L), and 20% w / w sodium chloride aqueous solution (450 mL) was added. The mixture was warmed to 50° C. and the pH was then adjusted to 7-8 with 10 M NaOH. The mixture was stirred for 30 minutes and the layers were separated. Drain the lower aqueous layer. Add 20% w / w sodium chloride aqueous solution (1.5L) and warm the contents to 50°C. Adjust the pH to 5 with 6M HCl. Stir the mixture for 20 minutes, separate the layers, and drain the lower aqueous layer. Add 20% w / w sodium chloride aqueous solution (1.5L) and warm the contents to 50°C. Stir the mixture for 20 minutes, separate the layers, and drain the lower aqueous layer. Add 20% w / w sodium chloride aqueous solution (1.5L) and warm the contents to 50°C. Stir the mixture for 20 minutes, separate the layers, and drain the lower aqueous layer. While adding fresh THF, vacuum distill the organic layer twice from 3L to 750mL. Dilute the organic layer to 3L with THF and grind and filter. Concentrate the organic layer to 750mL. Heat the mixture to 50°C to ensure complete dissolution. Cool the mixture to 40°C within 1 hour. At 40 ° C, 4- ((2- (benzyloxy) ethyl) sulfonylamino) -2- (6- azaspiro [2.5] octane -6- yl) benzoic acid seeds (2.5wt%) obtained from the previous batch were added, and the slurry was stirred for 1 hour. Toluene (5L / kg) was added at 40 ° C within 5 hours. The mixture was heated to 50 ° C and stirred for 1 hour. Toluene (5L / kg) was added at 50 ° C within 3 hours. The suspension was cooled to 20 ° C within 12 hours and stirred for 1 hour. The solid product was filtered. The filter cake was washed with pre-mixed 1: 2THF / toluene (900mL), and then washed with toluene (900mL). The filter cake was vacuum dried at 40 ° C under a stream of nitrogen, and the product 4- ((2- (benzyloxy) ethyl) sulfonylamino) -2- (6- azaspiro [2.5] octane -6- yl) benzoic acid was isolated as a crystalline solid with a yield of 79%. In the absence of seed crystals, the yield is less than about 1%. Melting point: 150.5℃-164.7℃; 1H NMR(500MHz,dmso-d6): δ10.38(br,1H),7.24-7.37(m,4H),7.19-7.23(m,2H),7.17(d d,1H),4.42(s,2H),3.79(t,2H),3.57(t,2H),2.94(t,4H),1.55(br,4H),0.41(s,4H); 13 C NMR (125MHz, dmso-d6): δ166.7,152.8,138.2,132.9,128.6,127.9,119.4,1 16.5,111.8,72.4,64.2,53.7,52.0,34.9,16.9,11.7; HRMS-ESI(m / z):[M+H] + , for [C 23 H 28 N2O5S+H] + Calculated value: 445.1792; measured value: 445.1782.

[0210] Example 6: Preparation of 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine

[0211]

[0212] 2-Chloro-6-methylpyrimidine-4-amine (commercially available, 150 g, 1.0 equiv), 4,4-difluoropiperidin-1-ium chloride (commercially available, 189 g, 1.15 equiv), acetonitrile (360 mL), water (240 mL) and triethylamine (148 g, 1.4 equiv) were added to the container. The suspension was stirred for 10 minutes, warmed to 80 ° C, and stirred for 16 hours. The mixture was cooled to 5 ° C, and 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidine-4-amine seeds (24 g1) obtained from the previous batch were added. The mixture was stirred for 15 minutes, and KOH aqueous solution (1.1 M, 150 mL) was added. The mixture was stirred for 1 hour, and KOH aqueous solution (1.1 M, 1.62 L) was added within 10 hours. The mixture was stirred for 1 hour and filtered. The filter cake was washed with a pre-stirred mixture of acetonitrile (60 mL) and water (540 mL). The filter cake was dried under vacuum at 60 °C and 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine was isolated as a crystalline solid in 89% yield. In the absence of seeding, the yield was about 1% or less. 1 H NMR (500MHz, dmso-d6): δ6.30 (bs, 2H), 5.64 (d, 0.7Hz, 1H), 3.79 (t, 5.8Hz, 4H), 2.06 (s, 3H), 1.90 (tt, 14.2, 5.8Hz, 4H); 13C NMR (125MHz, dmso-d6): δ164.4,164.4,160.8,123.4(t, 1 J C-F =-240.8Hz),93.7,40.1(t, 3 J C-F =5.1Hz),33.2(t, 2 J C-F =22.1Hz),23.7; 19 F NMR(471MHz,DMSO-d6)δ-94.7; HRMS-ESI(m / z):[M+H] + , for [C 23 H 28 N2O5S+H] + Calculated value: 445.1792; measured value: 445.1782.

[0213] Example 7: Preparation of 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine

[0214]

[0215] 4-((2-(Benzyloxy)ethyl)sulfonylamino)-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid (150.3 g, 1.0 eq), 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine (90.8 g, 1.2 eq) and chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH) (139.3 g, 1.5 eq), 2-MeTHF (1300 mL) and acetonitrile (150 mL) were added to the reaction vessel. 2,4,6-Trimethylpyridine (collidine) (109 mL, 2.5 eq) was added and the reaction mixture was stirred at 25 °C for 90 min. The reaction mixture was warmed to 50 °C and stirred for another 4 hours. After the reaction is complete, 2M NaOH solution (600mL) is added, followed by aqueous sodium chloride solution (600mL, 15wt%). The resulting mixture is stirred at 50°C for 10 minutes. The phases are separated, and the organic layer is further washed with an aqueous NaH2PO4 solution (1200mL, 25wt%). The resulting mixture is stirred at 50°C for 10 minutes. The phases are separated, and 1200mL of water is added to the organic layer. The resulting mixture is stirred at 50°C for 10 minutes, and the layers are separated. The organic layer is concentrated to a volume of approximately 525mL. 2-MeTHF (975mL) is added, and the organic layer is concentrated to a volume of approximately 525mL. 2-MeTHF (975mL) is added, and the organic layer is concentrated to a volume of approximately 525mL. 2-MeTHF (975mL) is added and charcoal (3g, 2wt%) is added. The resulting suspension is stirred at 20°C for 12 hours. The suspension is stirred at 40°C for 12 hours. Filter and wash with 150mL MeTHF. The filtered solution is warmed to 50 ° C. The mixture is inoculated with 2- (4,4-difluoropiperidin-1-yl) -6-methylpyrimidine -4-amine (1.5g, 1wt%) obtained from the previous batch, and stirred for 1h. The mixture is cooled to 35 ° C, and IPA (788mL) is added within 3 hours. The mixture is stirred for another 1 hour, and IPA (788mL) is added within 1h. The mixture is stirred for another 1h and cooled to 20 ° C. The mixture is stirred for 12 hours and filtered. The filter cake is washed with 2-MeTHF / IPA (25% MeTHF v / v, 600mL) and then washed with IPA (600mL, 2x). The filter cake is vacuum dried at 40 ° C for 24 hours. The product 2- (4,4-difluoropiperidin-1-yl) -6-methylpyrimidine -4-amine (173.3g, 80%) is isolated as an off-white crystalline solid. Without seed crystals, the yield is about 1% or less. Melting point = 156°C-160°C. 1H NMR (500MHz, DMSO-d6): δ13.29(s,1H),10.31(s,1H),8.03(d,J=8.6Hz,1H ),7.40(s,1H),7.30-7.21(m,6H),7.14(dd,J=8.7,2.1Hz,1H),4.41(s,2H) ,3.91-3.89(m,4H),3.80(t,J=5.8Hz,2H),3.56(t,J=5.9Hz,2H),2.91-2. 89(m,4H),2.31(s,3H),2.01-1.94(m,4H),1.91-1.52(m,4H),0.36(s,4H). 13 C NMR (126MHz, DMSO-d6): δ169.0,163.6,160.2,158.2,153.6,143.1,137.7,132.3,128.0,127.37,127.35,123.0(t ,J=241.0Hz),120.7,114.4,111.2,98.5,71.9,63.7,53.5,51.4,40.2,34.2,33.1(t,J=22.3Hz),24.3,16.8,11.1; 19 FNMR(471MHz,DMSO-d6)δ-94.8; HRMS-ESI(m / z):[M+H] + , for [C 33 H 40 F2N6O4S+H] + Calculated value: 655.2873; measured value: 655.2895.

[0216] Example 8: N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonyl Preparation of 2-(6-azaspiro[2.5]oct-6-yl)benzamide

[0217]

[0218] 2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-amine (700 g, 1.0 equiv), 10% Pd / C (105 g, 15 wt %, 50% wet), acetic acid (6 L) and water (1.05 L) were added to a hydrogenation vessel. The vessel was inerted with N2 (4 cycles) and placed under 45 psi H2. Hydrogenation was performed at 20°C for 25 hours. After the reaction was complete, the batch was filtered and the catalyst cake was rinsed with methyl isobutyl ketone (MIBK) (4.9 L). The filtrate was washed with water (7 L) and the aqueous layer was extracted twice with MIBK (2×3.5 L). The combined MIBK extracts were washed twice with aqueous NaOH (7 L, 3 wt %). The solution was concentrated to a total of 7 L and ground filtered. Grind filtration was supplemented with 2 L of MIBK rinse. The solution was concentrated under reduced pressure to a total of 1.5 volumes, heated to 100°C, and toluene (7L) was added. The solution was cooled to 85°C and inoculated with N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide (11g) obtained from the previous batch. The mixture was stirred at 85°C for 1 hour, cooled to 50°C within 3 hours, and heated to 70°C within 1 hour. The suspension was stirred at 70°C for 1 hour, and cooled to 15°C within 6 hours. The suspension was stirred at 15°C for 2 hours and filtered. The filter cake was rinsed with 2.1L toluene. The solid was dried in vacuo at 40°C. N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonylamino)-2-(6-azaspiro[2.5]octan-6-yl)benzamide was isolated as a crystalline product in 85% yield. In the absence of seed crystals, the yield was about 1% or less. 1 H NMR(500MHz,DMSO-d6)δ13.34(s,1H),10.23(s,1H),8.05(d,8.6Hz,1H),7.28(d,2.2Hz,1H),7.14(dd,8.6,2.2Hz,1H),4.93(t,6.2Hz,1H),3.9 0(bt,6.0Hz,4H),3.77(q,6.2Hz,2H),3.36(t,6.2Hz,2H),2.97(t,5.3H z,4H),2.30(s,3H),1.98(tt,13.8,6.0Hz,4H),1.72(m,4H),0.38(s,4H) 13 C NMR(126MHz,DMSO-d6)δ169.1,163.6,160.3,158.3,153.7,143.2,132.4,123.1(t, 1 J C-F=-241.0Hz),120.7,114.6,111.3,98.5,55.4,53.8,53.6,40.2(t, 3 J C-F =5.0Hz),33.1(t, 2 J C-F =22.3Hz),34.2,24.4,16.8,11.1; 19 F NMR(471MHz,DMSO-d6)δ-94.8; HRMS-ESI(m / z):[M+H] + , for [C 26 H 34 F2N6O4S+H] + Calculated value: 565.2409; measured value: 565.2407.

[0219] Example 9: N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonyl Preparation of 2-(6-azaspiro[2.5]octan-6-yl)benzamide hydrochloride

[0220]

[0221] N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide (100 g, 1.0 eq) was added to 1800 mL of premixed 8 / 1 acetone and water. The mixture was heated to 47°C and stirred at that temperature for 30 minutes. The solution was grinded and filtered, and the grinded filter was chased with 450 ml of premixed 8 / 1 acetone and water. To the mixture was added a solution of 150 mL of water and concentrated aqueous hydrochloric acid (1.2 eq of HCl, 24.3 g) at 47°C over 30 minutes. Water was added to the mixture (100 mL) and it was stirred at 47°C for 30 minutes. The reactor was cooled to 15°C over 4 hours. The batch was slurry milled to reduce the particle size. The product was isolated by filtration, washed with acetone (300 mL), and dried under vacuum at 40 °C to give N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonylamino)-2-(6-azaspiro[2.5]octan-6-yl)benzamide hydrochloride as a crystalline solid in 92% yield. 1H NMR(500MHz,DMSO-d6)δ13.87(bs,1H),10.41(s,1H),8.05(d,8.7Hz,1H),7.54(s,1H),7.34(d,2.2Hz,1H),7.19(dd,8.7,2.2Hz,1H),3.99(bt ,6.1Hz,4H),3.76(t,6.4Hz,2H),3.37(t,6.4Hz,2H),2.98(bt,5.3Hz,4H),2.47(s,3H),2.08(btt,13.6,6.1Hz,4H),1.69(m,4H),0.39(s,4H); 13 C NMR(126MHz,DMSO-d6)δ165.1,164.0,159.6,156.6,153.8,143.8,132.5,122.6(t, 1 J C-F =-241.2Hz),120.1,114.8,111.5,99.2,55.4,54.0,53.6,41.4,34.2,33.0(t, 2 J C-F =22.8Hz),21.9,16.8,11.2; 19 F NMR(471MHz,DMSO-d6)δ-95.0; HRMS-ESI(m / z):[M+H] + , for [C 26 H 34 F2N6O4S+H] + Calculated value: 565.2409; measured value: 565.2407.

[0222] The foregoing is merely illustrative of the present invention and is not intended to limit the present invention to the disclosed uses. Variations and modifications that are routine to those skilled in the art are intended to fall within the scope and nature of the present invention as defined by the appended claims. All references, patents, applications, and publications mentioned are incorporated herein by reference in their entirety as if written herein.

[0223] The practice of the methods disclosed herein and individual steps thereof can be performed manually and / or with the assistance of electronic devices or automation provided therefrom. Although many methods have been described with reference to specific embodiments, it will be readily appreciated by those skilled in the art that other means of performing actions associated with the methods may be used. For example, unless otherwise described, the order of the steps may be changed without departing from the scope or spirit of the methods. In addition, some individual steps may be combined, omitted, or further subdivided into other steps.

[0224] Unless otherwise indicated, the use of the terms "a / an", "the" and similar references in the context of the disclosure herein (especially in the context of the claims) should be interpreted to cover both the singular and the plural. Unless otherwise indicated herein, the description of the range of values ​​herein is intended only to be used as a shorthand method of referring to each individual value within the range individually, and each individual value is incorporated into the specification as if the value were individually described herein. Unless otherwise indicated, the use of any and all examples or exemplary language (e.g., "such as") provided herein is intended to better illustrate the disclosure herein and is not a limitation on the scope of the disclosure herein. The language in the specification should not be interpreted as indicating that any unclaimed element is necessary to practice the present disclosure.

Claims

1. A method for preparing a KIF18A inhibitor compound having the following chemical structure, The method comprises making a compound 2 having the following structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; react with a suitable deprotecting agent in a suitable solvent to form the compound 1.

2. The method according to claim 1, further comprising preparing the compound 2, comprising: Make compound 3 having the following formula: or its salts; wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 Alkyl, tetrahydropyranyl, allyl or benzyl; and a compound 4 having the formula: or its salts; The reaction is carried out in the presence of an amide coupling agent and a base in an organic solvent to form the compound 2.

3. The method according to claim 2, further comprising preparing the compound 3 or a salt thereof, comprising: Make compound 5 having the following formula: or its salts; With compound 6 having the following formula: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; M is a metal, and n is an integer selected from 1 or 2; or a hydrate thereof; and a base, optionally in the presence of a catalyst, in an organic solvent at an elevated temperature to form the compound 3 or a salt thereof.

4. The method according to claim 3, further comprising preparing the compound 5 or a salt thereof, comprising: Make compound 7 having the following formula: wherein X1 is a halide; and a compound having the formula 8 wherein LG1 is a leaving group; reacting in the presence of a base in an organic solvent at an elevated temperature to form the compound 5 or a salt thereof.

5. The method according to claim 2, further comprising preparing the compound 4, comprising: Make compound 9 having the following formula: wherein LG2 is a leaving group; and a compound 10 having the following formula: wherein X2 is a halide; reacting in the presence of a base at an elevated temperature in an organic solvent to form the compound 4.

6. A compound, which is wherein PG is benzyl (compound 2a).

7. A compound, which is wherein PG is benzyl (compound 3a).

8. A compound, which is or a salt thereof.

9. The method according to claim 3, further comprising preparing the compound 6 having the following chemical structure: wherein PG is a hydroxyl protecting group, M is a metal, and n is 1 or 2 (compound 6); or a hydrate thereof; the method comprising making a compound 11 having the following structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; react with a base in a polar solvent at a moderately elevated temperature to form the compound 6 or a hydrate thereof.

10. The method according to claim 9, further comprising preparing the compound 11 by: making a compound 12 having the following chemical structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 An alkyl group, a tetrahydropyranyl group, an allyl group or a benzyl group; and an oxidizing agent; in the presence of a catalyst in a solvent and at a slightly elevated temperature to form the compound 11.

11. The method according to claim 10, further comprising preparing the compound 12 by: making a compound 13 having the following chemical structure: With compound 14 having the following chemical structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; and LG3 is a leaving group; reacting in the presence of a base in a solvent and at a moderately elevated temperature to form the compound 12.

12. The method of claim 1, wherein PG is benzyl, and the suitable deprotecting agent is a palladium-carbon catalyst; or wherein the solvent is a polar solvent.

13. The method of claim 2, wherein: The amide coupling agent is selected from chloroformamidinium salt, 2-chloro-1,3-dimethylimidazolinium chloride (DMC), 1-(chloro-1-pyrrolidinylmethylene)pyrrolidinium hexafluorophosphate (PyCIU), 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) or N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ); wherein the base is selected from N-methylmorpholine (NMM), N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), 2,4,6-trimethylpyridine (collidine) or 2,6-lutidine; or The chloroformamidinium salt is chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (TCFH), and the base is 2,4,6-trimethylpyridine (collidine); or The method is carried out at a temperature of 25°C to 50°C, 40°C to 50°C or 50°C; or The solvent is an organic solvent selected from 2-methylTHF, acetonitrile, isopropyl acetate, dichloromethane, THF or a mixture thereof; or the solvent is 2-methylTHF and acetonitrile.

14. The method of claim 3, wherein: The process is carried out in the absence of a catalyst or in the presence of a metal catalyst selected from iron, gold or palladium catalysts; or wherein the process is carried out in the presence of a metal catalyst, wherein the catalyst is iron (III) chloride hexahydrate; or The base is sodium bisulfite; or The elevated temperature is at the reflux temperature of the solvent or 60°C to 100°C; 70°C to 90°C; or 70°C; or Wherein the solvent is NMP.

15. The method of claim 4, wherein: The base is a hydroxide or an amine; or wherein the base is potassium hydroxide or diisopropylethylamine; or wherein the base is potassium hydroxide; or The solvent is a polar aprotic solvent selected from NMP, DMAC, DMF or DMSO; or the solvent is NMP; or The elevated temperature is at the reflux temperature of the solvent or 80°C to 140°C; 100°C to 140°C; or 120°C; or The compound 5 is crystallized by adding an acid; or the acid is phosphoric acid.

16. The method of claim 5, wherein the base is an amine or a hydroxide; or the base is triethylamine; or The elevated temperature is at the reflux temperature of the solvent or 60°C to 100°C; 60°C to 85°C; or 80°C; or The solvent was a mixture of acetonitrile and water.

17. The method according to claim 9, wherein the base is a hydroxide, or the base is calcium hydroxide, sodium hydroxide; or the base is calcium hydroxide; or The solvent is C 1-6 A mixture of an alkyl alcohol and water; or The compound 6 is crystallized in acetone; or The temperature is 25°C to 50°C; 40°C to 50°C; or 50°C.

18. The method according to claim 10, wherein the oxidizing agent is a peroxide or a peroxycarboxylic acid; or the oxidizing agent is hydrogen peroxide or a meta-peroxycarboxylic acid; or The catalyst is sodium tungstate; or The temperature is 25°C to 40°C; 30°C to 35°C; or 30°C; or The solvent is a mixture of acetonitrile and water; or The compound 12 is crystallized in acetone or a mixture of acetone and water; or The compound 12 was not isolated and the solvent was acetonitrile.

19. The method of claim 11, wherein the base is a bicarbonate, a carbonate, a hydroxide or a phosphate; or wherein the base is calcium carbonate; or The solvent is alcohol, or the solvent is methanol; or The temperature is at the reflux temperature of the solvent or 70°C to 100°C; 75°C to 90°C; or 82°C.

20. The method according to any one of claims 1 to 5 or 9 to 19, further comprising reacting the compound 1 with an acid HA in a solvent to form a pharmaceutically acceptable salt of the compound 1 having the following formula: wherein the acid HX is HCl, methanesulfonic acid or p-toluenesulfonic acid; or the acid HX is HCl in DMSO; or wherein the solvent is water.

21. The method of any one of claims 1 to 5 or 9 to 20, wherein the PG is benzyl.

22. A compound having the following chemical structure: wherein PG is a hydroxy protecting group selected from C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 alkyl, tetrahydropyranyl, allyl or benzyl; preferably methyl-O-methyl, tetrahydropyranyl or benzyl; more preferably benzyl; M is a metal; and n is an integer selected from 1, 2 or 3; or a solid form thereof.

23. The compound of claim 22, wherein PG is benzyl, M is calcium, and n is 2 (compound 6a), having the structure or a solid form thereof.

24. The solid form of compound 6a according to claim 23, which is crystalline or amorphous.

25. The solid form of compound 6a according to claim 24, which is compound 6a-I having the following formula: The compound 6a-I is crystalline.

26. The crystalline compound 6a-1 according to claim 25, further characterized in that XRPD spectrum peaks at 4.2, 8.2 and 12.2 ± 0.2° 2θ using Cu Kα radiation; or further characterized by XRPD spectrum peaks at 13.6, 14.2, 18.3, 19.5, 20.6, 20.9, and 22.9 ± 0.2° 2θ using Cu Ka radiation; or further characterized by XRPD spectrum peaks at 16.2, 16.7, 19.2, 21.4, 23.9, 24.4, 24.7, 25.5, 27.6, 28.1, 30.3, 33.3, and 36.6 ± 0.2° 2θ using Cu Ka radiation; or having an XRPD pattern substantially as shown in Figure 1; or having a first endothermic transition at 124.96°C to 130.96°C; and a second endothermic transition at 256.11°C to 262.11°C; as measured by differential scanning calorimetry; or wherein the first endothermic transition is at 127.96°C ± 3°C; and the second endothermic transition is at 259.11°C ± 3°C; or having a thermogravimetric analysis (TGA) substantially as shown in Figure 3; or It has a single crystal structure substantially as shown in FIG. 4 .

27. The crystalline compound 6a-I of any one of claims 25 to 26, which is stable and has low hygroscopicity.

Citation Information

Cited By

  • Aliphatic calcium sulfinate and preparation method thereof

    CN115925589A